Davis Kaylan N, Hines Abigail E, Schaefer Margaret C, Naseman Kristina W
University of Kentucky College of Pharmacy, Lexington, KY.
University of Kentucky HealthCare, Lexington, KY.
Clin Diabetes. 2022 Summer;40(3):305-311. doi: 10.2337/cd21-0090.
This article provides an update on pharmacotherapy for diabetic nephropathy. ACE inhibitor or angiotensin 2 receptor blocker therapy is a standard of care for hypertension management in people with diabetes and albuminuria. Additionally, recent trials have elucidated the roles of additional therapeutic agents, including the sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 receptor agonists, and the recently approved mineralocorticoid receptor antagonist finerenone, in the treatment of chronic kidney disease in people with type 2 diabetes. This article provides an evidence-based review of therapies that may delay the progression of kidney disease in this population, including discussion of recent outcomes trials.
本文提供了糖尿病肾病药物治疗的最新进展。血管紧张素转换酶抑制剂或血管紧张素2受体阻滞剂疗法是糖尿病和蛋白尿患者高血压管理的标准治疗方法。此外，最近的试验阐明了其他治疗药物的作用，包括钠-葡萄糖协同转运蛋白2抑制剂、胰高血糖素样肽1受体激动剂，以及最近获批的盐皮质激素受体拮抗剂非奈利酮，在2型糖尿病患者慢性肾脏病治疗中的作用。本文对可能延缓该人群肾病进展的治疗方法进行了循证综述，包括对近期疗效试验的讨论。
